Redmile Group, LLC Zymeworks Inc. Transaction History

Redmile Group, LLC

  • $1.53 Billion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$4.65 - $7.43 $8.97 Million - $14.3 Million
1,930,000 Added 50.32%
5,765,818 $35.5 Million
Q2 2022

Aug 15, 2022
BUY
$4.82 - $7.7 $8.3 Million - $13.3 Million
1,721,621 Added 81.43%
3,835,818 $20.3 Million
Q1 2022

May 16, 2022
BUY
$6.0 - $16.98 $7.44 Million - $21.1 Million
1,239,800 Added 141.79%
2,114,197 $13.8 Million
Q4 2021

Feb 14, 2022
SELL
$15.19 - $29.33 $116,963 - $225,841
-7,700 Reduced 0.87%
874,397 $14.3 Million
Q3 2021

Nov 15, 2021
SELL
$27.35 - $37.28 $1.58 Million - $2.15 Million
-57,600 Reduced 6.13%
882,097 $25.6 Million
Q2 2021

Aug 16, 2021
SELL
$26.5 - $38.23 $1.22 Million - $1.76 Million
-46,003 Reduced 4.67%
939,697 $32.6 Million
Q1 2021

May 17, 2021
SELL
$29.83 - $56.81 $3.06 Million - $5.83 Million
-102,600 Reduced 9.43%
985,700 $31.1 Million
Q4 2020

Feb 16, 2021
SELL
$39.12 - $54.99 $520,295 - $731,367
-13,300 Reduced 1.21%
1,088,300 $51.4 Million
Q3 2020

Nov 16, 2020
BUY
$29.21 - $46.58 $9.29 Million - $14.8 Million
318,100 Added 40.6%
1,101,600 $51.3 Million
Q2 2020

Aug 14, 2020
SELL
$33.67 - $40.0 $2.87 Million - $3.4 Million
-85,100 Reduced 9.8%
783,500 $28.3 Million
Q1 2020

May 15, 2020
BUY
$24.28 - $49.8 $21.1 Million - $43.3 Million
868,600 New
868,600 $30.8 Million

Others Institutions Holding ZYME

# of Institutions
1
Shares Held
296K
Call Options Held
0
Put Options Held
0
View Full List

About Zymeworks Inc.

ZYME Quotes by TradingView
  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $882M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email